Literature DB >> 3892436

Community control of helminth infections of man by mass and selective chemotherapy.

R M Anderson, G F Medley.   

Abstract

The design of mass and targetted community-based chemotherapy programmes for the control of the major helminth infections of man is discussed in relation to the population and transmission dynamics of the parasites. Rapid reinfection following a single mass or targetted anthelmintic application is shown to be a universal feature of helminth transmission, as a consequence of the regulatory or feed-back mechanisms controlling population abundance within both individuals and the community as a whole. Control of reinfection requires repeated community treatment where the intensity of application and the interval between treatments are dependent on the reproductive life-expectancy of the adult worm, the net force of transmission prior to control (the basic reproductive rate) and the factors which create aggregation in the distribution of parasite loads within the population. Selective or targetted treatment is shown to be most effective for the control of morbidity as opposed to the control of transmission. The impact of targetted treatment depends critically on the factors that generate heterogeneity in parasite burdens and on whether or not selectivity is based on a single or repeated identification of the 'wormy' fraction of the community. Monte Carlo simulation studies are employed to assess the likely impacts of different control strategies on average parasite abundance/person and the distributions of parasite loads within populations. Future epidemiological research needs are discussed in relation to theoretical work and recent field studies of predisposition to heavy infection.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3892436     DOI: 10.1017/s0031182000052288

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  44 in total

1.  Control of clonorchiasis by repeated treatments with praziquantel.

Authors:  S T Hong; H J Rim; D Y Min; X Li; J Xu; Z Feng; S H Lee
Journal:  Korean J Parasitol       Date:  2001-12       Impact factor: 1.341

Review 2.  Helminthic infections.

Authors:  Shally Awasthi; D A P Bundy; Lorenzo Savioli
Journal:  BMJ       Date:  2003-08-23

3.  Modelling heterogeneity and the impact of chemotherapy and vaccination against human hookworm.

Authors:  L Sabatelli; A C Ghani; L C Rodrigues; P J Hotez; S Brooker
Journal:  J R Soc Interface       Date:  2008-11-06       Impact factor: 4.118

4.  On the solution of mathematical models of herd immunity in human helminth infections.

Authors:  M V José
Journal:  J Math Biol       Date:  1989       Impact factor: 2.259

5.  Ivermectin mass drug administration to humans disrupts malaria parasite transmission in Senegalese villages.

Authors:  Kevin C Kobylinski; Massamba Sylla; Phillip L Chapman; Moussa D Sarr; Brian D Foy
Journal:  Am J Trop Med Hyg       Date:  2011-07       Impact factor: 2.345

Review 6.  Human hookworm infection in the 21st century.

Authors:  Simon Brooker; Jeffrey Bethony; Peter J Hotez
Journal:  Adv Parasitol       Date:  2004       Impact factor: 3.870

7.  Ascaris reinfection of slum children: relation with the IgE response.

Authors:  I Hagel; N R Lynch; M C Di Prisco; E Rojas; M Pérez; N Alvarez
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

8.  Soil-transmitted helminthiases: nationwide survey in China.

Authors:  L Q Xu; S H Yu; Z X Jiang; J L Yang; L Q Lai; X J Zhang; C Q Zheng
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

9.  Predisposition to Trichuris trichiura infection in humans.

Authors:  D A Bundy; E S Cooper; D E Thompson; J M Didier; R M Anderson; I Simmons
Journal:  Epidemiol Infect       Date:  1987-02       Impact factor: 2.451

10.  Antagonism between two intestinal parasites in humans: the importance of co-infection for infection risk and recovery dynamics.

Authors:  Aaron D Blackwell; Melanie Martin; Hillard Kaplan; Michael Gurven
Journal:  Proc Biol Sci       Date:  2013-08-28       Impact factor: 5.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.